Core Viewpoint - XuanZhu Biotechnology Co., Ltd. (stock code: 02575.HK) was listed on the Hong Kong Stock Exchange on October 15, 2023, opening at HKD 29.46 and closing at HKD 26.30, marking a 126.72% increase from its issue price of HKD 11.60 [1][2][3]. Summary by Category Company Overview - XuanZhu Biotechnology is an innovative biopharmaceutical company based in China [1]. Share Issuance Details - A total of 67,333,500 shares were issued, with 6,733,500 shares available for public offering in Hong Kong and 57,233,500 shares for international offering [2][3]. - The total amount raised from the share issuance was HKD 781.1 million, with net proceeds of HKD 701.0 million after deducting estimated listing expenses of HKD 80.1 million [2][3]. Use of Proceeds - The net proceeds will be allocated to the research and commercialization of core products (KBP-3571, XZP-3287, and XZP-3621), development of key products (KM602, KM501, XZP-7797, and XZP-6924), funding for other candidate drugs (XZB-0004, XZP-5610, XZP-6019, and XZP-6877), enhancing commercialization and marketing capabilities, working capital, and other general corporate purposes [3]. Financial Performance - For the years 2023 and 2024, XuanZhu Biotechnology reported revenues of RMB 29,000 and RMB 30.1 million, respectively, with net losses of RMB 300.6 million and RMB 556.4 million [6][7]. - The company’s cash used in operating activities was RMB 116.0 million in 2023 and RMB 127.1 million in 2024 [8].
轩竹生物港股募7.8亿港元首日涨127% 近2年半均亏损